|
- Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments
- Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia
SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was hosted by the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research (SEACURE) at Nanyang Technological University (NTU), Singapore.
At the symposium, Neurophet operated an exhibition booth and showcased its major AI-powered brain imaging analysis solutions, including Neurophet AQUA AD, a software that supports monitoring of Alzheimer's disease treatment prescription, therapeutic effect, and adverse effects.
During the event, Hyunkook Lim, Chief Medical Officer (CMO) of Neurophet and Director of the Catholic Brain Health Center at Yeouido St. Mary's Hospital, along with Nagaendran Kandiah, a leading dementia expert and professor at the Lee Kong Chian School of Medicine, NTU, presented detailed use cases and clinical research outcomes involving Neurophet's AI-based brain imaging analysis solutions.
Hyunkook Lim, CMO of Neurophet, delivered a presentation titled "Neurophet a Game-Changer in Clinical Practice: Real-World Cases of Dementia Treatment Efficacy & Side Effect Management." He highlighted real-world cases from clinical settings in Korea using Neurophet AQUA AD and emphasized its clinical value in enhancing the safety of Alzheimer's disease treatment administration.
Professor Nagaendran Kandiah presented on the topic "Automatic Brain Segmentation in Cognitive Impairment: Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort." His detailed research finding demonstrated the clinical validity of Neurophet AQUA, a neurodegeneration imaging analysis software, in patients with mild cognitive impairment and dementia.
Jake Junkil Been, Co-CEO of Neurophet, stated, "By presenting the clinical value of Neurophet AQUA AD at this symposium, we further strengthened the evidence supporting its clinical utility," adding, "We plan to accelerate the expansion of Neurophet AQUA AD across healthcare institutions in the Southeast Asian region."
Meanwhile, the symposium concluded successfully with the participation of approximately 220 neurologists across six Southeast Asian countries, including Singapore, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
- Introduced brain-imaging analysis products, including Neurophet AQUA AD, which enables monitoring of adverse effects related to Alzheimer's disease treatments
- Highlighted clinical value of Neurophet AQUA AD…To accelerate efforts across healthcare institutions in Southeast Asia
SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon Kim), an artificial intelligence (AI) solution company for brain disorders diagnosis and treatment, announced on 9th that it participated in a symposium held on the 28th of last month (local time). The event was hosted by the Southeast Asian Consortium on Neurocognition, Neuroimaging and Biomarker Research (SEACURE) at Nanyang Technological University (NTU), Singapore.
At the symposium, Neurophet operated an exhibition booth and showcased its major AI-powered brain imaging analysis solutions, including Neurophet AQUA AD, a software that supports monitoring of Alzheimer's disease treatment prescription, therapeutic effect, and adverse effects.
During the event, Hyunkook Lim, Chief Medical Officer (CMO) of Neurophet and Director of the Catholic Brain Health Center at Yeouido St. Mary's Hospital, along with Nagaendran Kandiah, a leading dementia expert and professor at the Lee Kong Chian School of Medicine, NTU, presented detailed use cases and clinical research outcomes involving Neurophet's AI-based brain imaging analysis solutions.
Hyunkook Lim, CMO of Neurophet, delivered a presentation titled "Neurophet a Game-Changer in Clinical Practice: Real-World Cases of Dementia Treatment Efficacy & Side Effect Management." He highlighted real-world cases from clinical settings in Korea using Neurophet AQUA AD and emphasized its clinical value in enhancing the safety of Alzheimer's disease treatment administration.
Professor Nagaendran Kandiah presented on the topic "Automatic Brain Segmentation in Cognitive Impairment: Validation of AI-based AQUA Software in the Southeast Asian BIOCIS Cohort." His detailed research finding demonstrated the clinical validity of Neurophet AQUA, a neurodegeneration imaging analysis software, in patients with mild cognitive impairment and dementia.
Jake Junkil Been, Co-CEO of Neurophet, stated, "By presenting the clinical value of Neurophet AQUA AD at this symposium, we further strengthened the evidence supporting its clinical utility," adding, "We plan to accelerate the expansion of Neurophet AQUA AD across healthcare institutions in the Southeast Asian region."
Meanwhile, the symposium concluded successfully with the participation of approximately 220 neurologists across six Southeast Asian countries, including Singapore, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam.
About Neurophet
Neurophet specializes in developing solutions for diagnosis support, treatment guides, and treatment devices targeting brain disorders based on cutting-edge artificial intelligence (AI) technology. The company was founded in 2016 by Co-CEOs Jake Junkil Been and Donghyeon Kim, who developed the next-generation neuro-navigation system.
Major products include brain MRI analysis software "Neurophet AQUA", PET Image Quantitative Analysis Software "Neurophet SCALE PET", Brain imaging treatment planning software for electric and magnetic brain stimulation "Neurophet tES/TMS LAB", Alzheimer's Disease treatment prescription and monitoring software "Neurophet AQUA AD" for tracking treatment efficacy and side effects, and Multiple Sclerosis image analysis software "Neurophet AQUA MS".
Neurophet has set its top priority to helping patients suffering from brain disorders. Based on expertise in neuroscience, Neurophet will continue to challenge and grow to explore the human brain's health and pioneer solutions for brain diseases with AI technology.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Neurophet Introduced Use Cases of Its AI-based Brain Imaging Analysis Solutions at the SEACURE Symposium Hosted by Nanyang Technological University in Singapore
SHENZHEN, China, April 2, 2026 /PRNewswire/ -- X Square Robot, an emerging leader in embodied AI and humanoid robotics, announced the successful conclusion of the world's first Embodied AI Developers Conference (EAIDC 2026), the first global gathering dedicated specifically to developers building embodied AI systems.
EAIDC 2026 marks one of the first large-scale industry gatherings dedicated to embodied AI, bringing together leading researchers, developers, and technology companies to accelerate the transition of intelligent systems from laboratory research to real-world applications. The event features live robotic demonstrations, a national-level hackathon, and discussions between academia and industry focused on deployment, commercialization, and ecosystem development.
EAIDC 2026, the world's first embodied intelligence developer competition, is designed to accelerate real-world innovation through hands-on collaboration and deployment-focused challenges.
X Square Robot hosted EAIDC as part of a broader effort to contribute to the global embodied AI ecosystem and expand its role in shaping the future of intelligent systems. The competition also introduced a set of "three firsts" designed to bring embodied AI development closer to real-world conditions, including real-robot task execution, continuous system evaluation, and full end-to-end deployment workflows. Task design focused on four core capability areas — grasping and placement, language understanding, fine manipulation, and long-horizon decision-making — with participants completing challenges such as ring placement, instruction-based fruit sorting, cable plugging, and word spelling. A full-variable evaluation approach required teams to operate without preset parameters, using randomized real-world environments to test true adaptability and model robustness.
The company is operating at a time of growing global momentum around humanoid robotics, as advances in physical AI and vision-language-action (VLA) models begin to unlock more complex, real-world capabilities. The company has raised approximately $280 million to date, with backing from investors including Alibaba, ByteDance, Meituan, HongShan (formerly Sequoia China), and other leading technology and venture firms.
X Square Robot is focused on developing general-purpose humanoid systems capable of operating in dynamic, unstructured environments. Its technology centers on embodied foundation models designed to enable robots to perceive, adapt, and perform tasks across a range of real-world scenarios.
The company has begun generating early revenue from deployments across sectors including education, hospitality, and elder care, and is exploring broader applications in household services through collaborations such as its partnership with 58.com. The company has also been active in advancing technical research and industry engagement, including participation in global AI forums and academic communities such as CVPR, reflecting its commitment to contributing to both the development and commercialization of embodied intelligence.
These efforts reflect a broader industry shift toward applying AI-driven robotics to address labor shortages and operational challenges in both consumer and commercial environments.
By hosting EAIDC 2026, X Square Robot is engaging with a growing global ecosystem of developers and industry stakeholders working to define the next generation of intelligent systems. The company views this as part of a broader strategy to expand its international presence and establish itself as a global innovator in embodied AI.
For more information, visit https://x2robot.com/.
About X Square Robot
X Square Robot is a global innovator in embodied artificial intelligence, robotics, and autonomous systems. The company develops integrated software and hardware platforms that enable robots to perceive, reason, and act safely in complex environments. Partnering with leading universities and technology institutions, X Square Robot delivers scalable AI infrastructure and establishes open benchmarks to drive worldwide progress in intelligent robotics.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
X Square Robot Hosts Inaugural EAIDC 2026, Advancing Real-World Deployment of Embodied AI
